A Phase 1, Open-label, Multicohort Study to Evaluate the Impact of Inhibitors and Inducers of Cytochrome P450 Enzyme (CYP)3A, P-glycoprotein (P-gp), and Breast Cancer Resistant Protein (BCRP) on the Pharmacokinetics (PK) of Vesatolimod (VES) in Virologically Suppressed Adults With HIV-1 on Antiretroviral Therapy (ART)
The goal of this clinical study is to learn more about the impact of cobicistat (COBI) (P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), and strong cytochrome P450 enzyme [CYP]3A inhibitor), voriconazole (VOR) (strong CYP3A inhibitor), and rifabutin (RFB) (moderate CYP3A inducer) on the study drug, vesatolimod (VES), in people with HIV-1 on antiretroviral therapy (ART).
View MoreAge
18 Years +
Sex
All
Healthy Volunteers
No
Medical Condition
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Gender
N/A
Date
August 2022 - October 2023
Study Type
Interventional
Study Phase
Phase 1
Product
Vesatolimod, Cobicistat, Voriconazole, Rifabutin
Long Beach, California, United States, 90806
Miami, Florida, United States, 33014
Miami, Florida, United States, 33147
West Palm Beach, Florida, United States, 33407
Marlton, New Jersey, United States, 08054
Share Trial